Dr. Lea Cunningham, Principal Investigator, and Dr. Alan Cantor, Associate Investigator, dive into the rationale behind this groundbreaking Phase 1b clinical trial investigating the potential of the drug imatinib to increase RUNX1 protein levels in individuals with RUNX1-FPD.